Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Kwang Hyuck Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2898-6233; OpenAlex author ID A5102908811. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
69
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper, 1 trial · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 20

  1. Prognostic Value of Pseudotime from Texture Parameters of [18F]fluorodeoxyglucose PET/CT in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.acra.2025.10.016↗
  2. Evaluation of Exosome-derived Small RNAs as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma Using Next-generation Sequencing. Co-author DOI 10.3343/alm.2025.0121↗
  3. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  4. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
  5. Prognostic Significance of 18 F-FDG PET/CT Radiomics in Patients With Resectable Pancreatic Ductal Adenocarcinoma Undergoing Curative Surgery. Co-author DOI 10.1097/rlu.0000000000005363↗
  6. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.1101/2023.02.15.23286007↗
  7. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.21203/rs.3.rs-2578124/v1↗
  8. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2021.101321↗
  9. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker. Co-author DOI 10.3389/fonc.2020.616440↗
  10. Preoperative EUS-guided FNA: effects on peritoneal recurrence and survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.gie.2018.06.024↗
  11. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. Co-author DOI 10.1038/s41598-018-30100-w↗
  12. Comparison of 22-gauge standard fine needle versus core biopsy needle for endoscopic ultrasound-guided sampling of suspected pancreatic cancer: a randomized cr… Last author DOI 10.1080/00365521.2017.1390597↗
  13. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcino… Last author DOI 10.18632/oncotarget.13864↗
  14. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Co-author DOI 10.18632/oncotarget.17463↗
  15. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00259-016-3316-6↗
  16. Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. Co-author DOI 10.1097/mpa.0000000000000346↗
  17. [Chemo-sensitivity study in pancreatic cancer]. Co-author DOI 10.4166/kjg.2014.64.6.317↗
  18. Clinicoradiologic characteristics and outcomes of metastatic cancer to the pancreas and double primary pancreatic cancer. Co-author DOI 10.1016/j.clinre.2012.05.013↗
  19. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/pmic.201200101↗
  20. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer. First author DOI 10.1097/mpa.0b013e318252f4f5↗

Trials 1

  1. Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Suspected Unresectable Pancreatic Cancer Principal investigator NCT01876069↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyu Taek Lee · 11 shared papers, 2012–2025 · strength 1.20
  2. Joo Kyung Park · 9 shared papers, 2017–2025 · strength 1.16
  3. Jong Kyun Lee · 10 shared papers, 2012–2024 · strength 0.94
  4. Jin Seok Heo · 5 shared papers, 2012–2026 · strength 0.84
  5. Joon Young Choi · 3 shared papers, 2016–2026 · strength 0.63
  6. Seung Hyup Hyun · 3 shared papers, 2016–2026 · strength 0.63
  7. Hye Min Kim · 4 shared papers, 2020–2023 · strength 0.52
  8. Jeong Il Yu · 2 shared papers, 2024–2026 · strength 0.52
  9. Young Hoon Choi · 3 shared papers, 2023–2025 · strength 0.50
  10. Jong Kyun Lee · 4 shared papers, 2012–2025 · strength 0.42
  11. Wonseok Whi · 1 shared paper, 2026 · strength 0.33
  12. Jin‐Young Jang · 2 shared papers, 2023 · strength 0.28
  13. Youngil Koh · 2 shared papers, 2023 · strength 0.28
  14. Hyung Rae Kim · 2 shared papers, 2023 · strength 0.28
  15. Sung‐Soo Yoon · 2 shared papers, 2023 · strength 0.28
  16. Daechan Park · 2 shared papers, 2023 · strength 0.28
  17. Joon Oh Park · 2 shared papers, 2016–2024 · strength 0.24
  18. Jang Yoo · 1 shared paper, 2024 · strength 0.24
  19. Hyemin Kim · 1 shared paper, 2025 · strength 0.22
  20. Jin Ho Choi · 1 shared paper, 2025 · strength 0.22
  21. Semin Lee · 1 shared paper, 2025 · strength 0.22
  22. Kee‐Taek Jang · 3 shared papers, 2015–2018 · strength 0.19
  23. In Woong Han · 1 shared paper, 2024 · strength 0.18
  24. Kyunga Kim · 1 shared paper, 2024 · strength 0.18
  25. Sang Hyun Shin · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.